Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

Trial Profile

Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Arteriovenous malformations
  • Focus Therapeutic Use
  • Acronyms MAV-RAPA
  • Most Recent Events

    • 02 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 25 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top